Plasmodium falciparum malaria
ICD-10 B53.0 is a billable code used to indicate a diagnosis of plasmodium falciparum malaria.
Plasmodium falciparum malaria is a severe form of malaria caused by the Plasmodium falciparum parasite, which is transmitted to humans through the bite of infected Anopheles mosquitoes. This species is responsible for the majority of malaria-related morbidity and mortality worldwide. Clinical manifestations can range from mild flu-like symptoms to severe complications such as cerebral malaria, acute respiratory distress syndrome, and multi-organ failure. Diagnosis is typically confirmed through blood smears or rapid diagnostic tests that identify the presence of the parasite. Treatment involves the use of antimalarial medications, with artemisinin-based combination therapies being the first-line treatment. However, resistance to these medications has been reported in some regions, complicating treatment protocols. Prophylaxis is recommended for travelers to endemic areas, utilizing medications such as atovaquone-proguanil or mefloquine to prevent infection. Understanding the epidemiology, clinical presentation, and treatment options for Plasmodium falciparum malaria is crucial for effective management and coding.
Detailed clinical notes on symptoms, travel history, and laboratory results.
Patients presenting with fever and travel history to endemic areas.
Ensure accurate species identification and treatment response documentation.
Documentation of prophylaxis measures taken and patient education provided.
Pre-travel consultations for individuals traveling to malaria-endemic regions.
Emphasize the importance of preventive measures and adherence to prophylaxis.
Used to confirm diagnosis in patients presenting with symptoms.
Document the reason for the test and results.
Infectious disease specialists should ensure comprehensive testing.
The primary treatment is artemisinin-based combination therapy (ACT), which is effective against this species of malaria.
